Immunophotonics, Inc. is a pioneering biotechnology company based in Saint Louis, MO, dedicated to unlocking the potential of the immune system through the development of a new class of therapeutics. Their proprietary glycan polymer technology stimulates antigen capture and uptake, triggering an immune response that enables the rejection of cancer and other diseases. With practical applications in interventional oncology, immunotherapy, and vaccine enhancement, Immunophotonics aims to elevate modern medicine and improve outcomes for patients worldwide.
Through their innovative approach, Immunophotonics is transforming conventional surgical interventions into systemically active immunotherapies, upregulating T-cell activation, downregulating T-cell exhaustion, and driving stronger immune responses. Their powerful immunoadjuvant, IP-001, has the potential to enhance antigen-specific immunity against infectious diseases, including SARS-CoV-2, and increase the efficacy of vaccines. Committed to global human health, Immunophotonics is at the forefront of advancing medical treatments and improving patient outcomes.
Generated from the website